{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000003","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.753405+00:00","generated_at":"2026-05-28T03:40:59.716143+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M","bullets":["Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.","LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.","2025 guidance: global net product sales $420-435M with positive cash flow from operations.","Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.","Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000003","json":"https://secwatch.observer/filing/0001759425-25-000003.json","markdown":"https://secwatch.observer/filing/0001759425-25-000003.md","text":"https://secwatch.observer/filing/0001759425-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/0001759425-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000003/mirm-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:40:59.716143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}